RET G810A

CI-VAR-00001831Explore in graph →NP_066124.1:p.Gly810AlaNM_020975.6:c.2429G>CCIViC 1689

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma2
KIF5B::RET Fusion AND RET G810A	Lenvatinib + PonatinibSubstitutes	Predictive	D	Supports Sensitivity Response	3	submitted	EID4853 We established inducible KIF5B-RET transgenic mice and KIF5B-RET-dependent cell lines for preclinical modeling of KIF5B-RET-associated lung adenocarcinoma. By culturing cells with increasing concentra… (full text at CIViC) PMID 27496134 · Huang et al., 2016 · Open in CIViC	civic
KIF5B::RET Fusion AND RET G810A	Vandetanib	Predictive	D	Does Not Support Resistance	3	submitted	EID4852 We established inducible KIF5B-RET transgenic mice and KIF5B-RET-dependent cell lines for preclinical modeling of KIF5B-RET-associated lung adenocarcinoma. By culturing cells with increasing concentra… (full text at CIViC) PMID 27496134 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.